Last updated on February 2020

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis


Brief description of study

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.

Clinical Study Identifier: NCT03773978

Find a site near you

Start Over

Centro Medico Privado de Reumatologia

San Miguel de Tucuman, Argentina
  Connect »

LKH Bregenz

Bregenz, Austria
  Connect »

AKH

Wien, Austria
  Connect »

UCL- Saint Luc

Brussels, Belgium
  Connect »

CHRU Nancy Brabois - H pital d'Enfants

Vandoeuvre les Nancy Cedex, France
  Connect »

Center of Children`s Health

Moscow, Russian Federation
  Connect »

Great Ormond Street Hospital

Bloomsbury, United Kingdom
  Connect »